European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)
(2019) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 11. p.538-549- Abstract
Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists. Methods: EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety,... (More)
Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists. Methods: EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization. Results: The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials. Discussion: The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.
(Less)
- author
- organization
- publishing date
- 2019-12-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease (AD), Magnetic resonance imaging (MRI), Mild cognitive impairment (MCI), Parkinson's disease (PD), Subjective cognitive decline (SCD), Ultrahigh-field MRI, Vascular dementia
- in
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- volume
- 11
- pages
- 12 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:31388558
- scopus:85069944986
- ISSN
- 2352-8729
- DOI
- 10.1016/j.dadm.2019.04.010
- language
- English
- LU publication?
- yes
- id
- 272479cd-e296-4817-ad09-0efbad8da5f9
- date added to LUP
- 2019-08-30 13:31:55
- date last changed
- 2024-09-04 07:38:17
@article{272479cd-e296-4817-ad09-0efbad8da5f9, abstract = {{<p>Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists. Methods: EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization. Results: The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials. Discussion: The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.</p>}}, author = {{Düzel, Emrah and Acosta-Cabronero, Julio and Berron, David and Biessels, Geert Jan and Björkman-Burtscher, Isabella and Bottlaender, Michel and Bowtell, Richard and Buchem, Mark v. and Cardenas-Blanco, Arturo and Boumezbeur, Fawzi and Chan, Dennis and Clare, Stuart and Costagli, Mauro and de Rochefort, Ludovic and Fillmer, Ariane and Gowland, Penny and Hansson, Oskar and Hendrikse, Jeroen and Kraff, Oliver and Ladd, Mark E. and Ronen, Itamar and Petersen, Esben and Rowe, James B. and Siebner, Hartwig and Stoecker, Tony and Straub, Sina and Tosetti, Michela and Uludag, Kamil and Vignaud, Alexandre and Zwanenburg, Jaco and Speck, Oliver}}, issn = {{2352-8729}}, keywords = {{Alzheimer's disease (AD); Magnetic resonance imaging (MRI); Mild cognitive impairment (MCI); Parkinson's disease (PD); Subjective cognitive decline (SCD); Ultrahigh-field MRI; Vascular dementia}}, language = {{eng}}, month = {{12}}, pages = {{538--549}}, publisher = {{Elsevier}}, series = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}}, title = {{European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)}}, url = {{http://dx.doi.org/10.1016/j.dadm.2019.04.010}}, doi = {{10.1016/j.dadm.2019.04.010}}, volume = {{11}}, year = {{2019}}, }